BACKGROUND: Expression of mucin antigen MUC1 and down regulation of MUC2 are associated with adverse prognosis in colorectal cancer (CRC), but their prognostic significance with respect to differing DNA mis- match repair (MMR) status is poorly understood. OBJECTIVE: To determine the prognostic significance of MUC1 and MUC2 in CRC with different MMR statuses. METHODS: Using the tissue microarray (TMA) technique, a series of 1420 unselected, non-consecutive CRC resections was subdivided into three groups: (1) MMR-proficient; (2) MLH1-negative; and (3) presumed hereditary non-polyposis colon cancer (HNPCC). Immunohistochemical analysis of MUC1 and MUC2 expression (>0%) and loss (0%) was performed, and the results were correlated with clinicopathological parameters. RESULTS: In MMR-proficient CRC, MUC1 expression was more frequently found in tumours with higher tumour stage (p=0.004) and higher tumour grade (p=0.041) and loss of MUC2 was associated with higher tumour stage (p=0.028), node stage (p=0.001), presence of vascular invasion (p=0.028) and worse survival (p=0.034). In MLH1-negative CRC, MUC2 loss was associated with the presence of lymph node metastasis (p=0.028) and worse survival (p=0.015), but there was no association between MUC1 expression and clinicopathological features. In presumed HNPCC, MUC1 expression and MUC2 loss were not associated with clinicopathological parameters. CONCLUSIONS: Mucins have a prognostic significance in sporadic CRC, but not in hereditary CRC. Loss of MUC2 is an adverse prognostic factor in MMR-proficient and MLH1-negative CRC, whereas MUC1 expression is associated with tumour progression in MMR-proficient CRC only.
BACKGROUND: Expression of mucin antigen MUC1 and down regulation of MUC2 are associated with adverse prognosis in colorectal cancer (CRC), but their prognostic significance with respect to differing DNA mis- match repair (MMR) status is poorly understood. OBJECTIVE: To determine the prognostic significance of MUC1 and MUC2 in CRC with different MMR statuses. METHODS: Using the tissue microarray (TMA) technique, a series of 1420 unselected, non-consecutive CRC resections was subdivided into three groups: (1) MMR-proficient; (2) MLH1-negative; and (3) presumed hereditary non-polyposis colon cancer (HNPCC). Immunohistochemical analysis of MUC1 and MUC2 expression (>0%) and loss (0%) was performed, and the results were correlated with clinicopathological parameters. RESULTS: In MMR-proficient CRC, MUC1 expression was more frequently found in tumours with higher tumour stage (p=0.004) and higher tumour grade (p=0.041) and loss of MUC2 was associated with higher tumour stage (p=0.028), node stage (p=0.001), presence of vascular invasion (p=0.028) and worse survival (p=0.034). In MLH1-negative CRC, MUC2 loss was associated with the presence of lymph node metastasis (p=0.028) and worse survival (p=0.015), but there was no association between MUC1 expression and clinicopathological features. In presumed HNPCC, MUC1 expression and MUC2 loss were not associated with clinicopathological parameters. CONCLUSIONS: Mucins have a prognostic significance in sporadic CRC, but not in hereditary CRC. Loss of MUC2 is an adverse prognostic factor in MMR-proficient and MLH1-negative CRC, whereas MUC1 expression is associated with tumour progression in MMR-proficient CRC only.
Authors: A Nocito; L Bubendorf; E M Tinner; K Süess; U Wagner; T Forster; J Kononen; A Fijan; J Bruderer; U Schmid; D Ackermann; R Maurer; G Alund; H Knönagel; M Rist; M Anabitarte; F Hering; T Hardmeier; A J Schoenenberger; R Flury; P Jäger; J L Fehr; P Schraml; H Moch; M J Mihatsch; T Gasser; G Sauter Journal: J Pathol Date: 2001-07 Impact factor: 7.996
Authors: J Torhorst; C Bucher; J Kononen; P Haas; M Zuber; O R Köchli; F Mross; H Dieterich; H Moch; M Mihatsch; O P Kallioniemi; G Sauter Journal: Am J Pathol Date: 2001-12 Impact factor: 4.307
Authors: R Simon; A Nocito; T Hübscher; C Bucher; J Torhorst; P Schraml; L Bubendorf; M M Mihatsch; H Moch; K Wilber; A Schötzau; J Kononen; G Sauter Journal: J Natl Cancer Inst Date: 2001-08-01 Impact factor: 13.506
Authors: M Bärlund; F Forozan; J Kononen; L Bubendorf; Y Chen; M L Bittner; J Torhorst; P Haas; C Bucher; G Sauter; O P Kallioniemi; A Kallioniemi Journal: J Natl Cancer Inst Date: 2000-08-02 Impact factor: 13.506
Authors: S E Baldus; S P Mönig; F-G Hanisch; T K Zirbes; U Flucke; S Oelert; G Zilkens; B Madejczik; J Thiele; P M Schneider; A H Hölscher; H P Dienes Journal: Histopathology Date: 2002-05 Impact factor: 5.087
Authors: J R Jass; H Iino; A Ruszkiewicz; D Painter; M J Solomon; D J Koorey; D Cohn; K L Furlong; M D Walsh; J Palazzo; T B Edmonston; R Fishel; J Young; B A Leggett Journal: Gut Date: 2000-07 Impact factor: 23.059
Authors: Alessandro Lugli; Inti Zlobec; Parham Minoo; Kristi Baker; Luigi Tornillo; Luigi Terracciano; Jeremy R Jass Journal: Hum Pathol Date: 2006-05-26 Impact factor: 3.466
Authors: Mrunal V Kesari; Vandana L Gaopande; Avinash R Joshi; Shreedhar V Babanagare; Bageshree P Gogate; Ameya V Khadilkar Journal: Indian J Gastroenterol Date: 2015-03-04
Authors: Adam Elzagheid; Fatma Emaetig; Abdelbaset Buhmeida; Matti Laato; Omran El-Faitori; Kari Syrjänen; Yrjö Collan; Seppo Pyrhönen Journal: Tumour Biol Date: 2012-11-21